Current concepts of the role of oxidized LDL receptors in atherosclerosis

Current Atherosclerosis Reports

Volumn 14, Issue 2, 2012, Pages 150-159

  Goyal, Tanu ^a   Mitra, Sona ^a   Khaidakov, Magomed ^a   Wang, Xianwei ^a   Singla, Sandeep ^a   Ding, Zufeng ^a   Liu, Shijie ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atherosclerosis; CD36; LOX1; Scavenger receptors; SRA 1

Indexed keywords

CD36 ANTIGEN; COLLAGEN; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR A;

APOPTOSIS; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DISEASE ACTIVITY; DISEASE COURSE; DOWN REGULATION; FOAM CELL; HUMAN; INFLAMMATORY CELL; LIPID STORAGE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DENSITY; REVIEW; SMOOTH MUSCLE FIBER;

EID: 84862776951     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0228-1     Document Type: Review

References (83)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
2. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91 (3A):7A-11A. (Pubitemid 36351457)
3. Libby P. Inflammation in atherosclerosis. Nature. 2002;420 (6917):868-74. (Pubitemid 36019640)
4. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley white lecture 1995. Circulation. 1996;94(8):2013-20. (Pubitemid 26349317)
5. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis. 2002;44(5):349-56. (Pubitemid 34535156)
6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840-4.
7. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 1987;84(16):5928-31.
8. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, et al. The binding of oxidized low density lipoprotein [ox-LDL] to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem. 2001;276(17):13750-5.
9. Roy Chowdhury SK, Sangle GV, Xie X, Stelmack GL, Halayko AJ, Shen GX. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab. 2010;298(1):E89-98. The findings in this article suggest that extensively oxidized LDL impairs enzymes in the mitochondrial respiratory chain and increases ROS in endothelial cells, which may contribute to vascular injury and pathogenesis of atherosclerosis.
10. Hsieh CC, Yen MH, Yen CH, Lau YT. Oxidized low density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells. Cardiovasc Res. 2001;49 (1):135-45.
11. Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res. 2009;104(2):210-8. 21p following 218. This article states the pathway involved in the proatherogenic activation of macrophages via minimally oxidized LDL leading to generation of ROS increased expression of proinflammatory cytokines and migration of smooth muscle cells.
12. Chen H, Li D, Saldeen T, Mehta JL. Transforming growth factorbeta[ 1] modulates oxidatively modified LDL-induced expression of adhesion molecules: role of LOX-1. Circ Res. 2001;89 (12):1155-60. (Pubitemid 34627873)
13. Martens JS, Lougheed M, Gomez-Munoz A, Steinbrecher UP. A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem. 1999;274(16):10903-10.
14. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem. 2008;283(16):10226-31.
15. Chai YC, Binion DG, Macklis R, Chisolm III GM. Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidylcholine. Evidence for FGF-2 release from cells not extracellular matrix. Vascul Pharmacol. 2002;38(4):229-37. (Pubitemid 36398268)
16. Chatterjee S, Ghosh N. Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation. Glycobiology. 1996;6 (3):303-11. (Pubitemid 26156450)
17. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J. 2011;25(5):1718-1728. This article reports the role of ox-LDL in miRNA-mediated epigenetic regulation in atherosclerosis. It shows that ox-LDL upregulates miR-29b expression, leading to epigenetic modification in MMP-2/ MMP-9 genes, which increased human aortic smooth muscle migration.
18. Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J, et al. Modulation of ADP-induced platelet activation by aspirin and Pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and insideout integrin signaling. J Pharmacol Exp Ther. 2007;322(3):1324-32. (Pubitemid 47295783)
19. Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis. 2001;156(1):119-25. (Pubitemid 32429602)
20. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92(6):1565-9.
21. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103(15):1955-60. (Pubitemid 32322222)
22. Yamashita H, Ehara S, Yoshiyama M, Naruko T, Haze K, Shirai N, et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J. 2007;71(5):681-7. (Pubitemid 46683357)
23. Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandao SA, Povoa RM, et al. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin Chim Acta. 2009;406(1-2):113-118. This article explores the role of IgG anti-ox-LDL antibodies in relation to acute vascular events and reported that these antibodies could be protective in atherosclerosis as acute events are associated with decreased titres.
24. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized lowdensity lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360-70. (Pubitemid 36164488)
25. Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods. 2007;43(3):207-17. (Pubitemid 47499075)
26. de Beer MC, Zhao Z, Webb NR, van der Westhuyzen DR, de Villiers WJ. Lack of a direct role for macrosialin in oxidized LDL metabolism. J Lipid Res. 2003;44(4):674-85. (Pubitemid 37279669)
27. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277(51):49982-8. (Pubitemid 36014449)
28. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol. 2001;12(5):489-95. (Pubitemid 32980296)
29. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997;386(6622):292-6. (Pubitemid 27142516)
30. Babaev VR, Gleaves LA, Carter KJ, Suzuki H, Kodama T, Fazio S, et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2000;20(12):2593-9.
31. Sakaguchi H, Takeya M, Suzuki H, Hakamata H, Kodama T, Horiuchi S, et al. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Invest. 1998;78 (4):423-34. (Pubitemid 28207855)
32. de Winther MP, van Dijk KW, van Vlijmen BJ, Gijbels MJ, Heus JJ, Wijers ER, et al. Macrophage specific overexpression of the human macrophage scavenger receptor in transgenic mice, using a 180-kb yeast artificial chromosome, leads to enhanced foam cell formation of isolated peritoneal macrophages. Atherosclerosis. 1999;147(2):339-47. (Pubitemid 29512266)
33. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, et al. CD36, a novel receptor for oxidized lowdensity lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1999;19(5):1333-9. (Pubitemid 29227655)
34. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006;4(3):211-21. (Pubitemid 44283954)
35. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105(8):1095-108. (Pubitemid 30217694)
36. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidasegenerated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103(11):1547-60.
37. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105(8):1049-56. (Pubitemid 30217689)
38. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest. 1995;96(4):1859-65.
39. Kuchibhotla S, Vanegas D, Kennedy DJ, Guy E, Nimako G, Morton RE, et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc Res. 2008;78 (1):185-96. (Pubitemid 351430949)
40. Makinen PI, Lappalainen JP, Heinonen SE, Leppanen P, Lahteenvuo MT, Aarnio JV, et al. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc Res. 2010;88(3):530-538. SR-A and CD36 play a role in foam cell formation via uptake of modified LDL, and silencing of each leads to decrease in atherosclerosis; however, silencing of both leads to reciprocal upregulation of these receptors, thus ameliorating the protective effects of their silencing.
41. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005;115(8):2192-201. (Pubitemid 41134161)
42. de Winther MP, Hofker MH. Scavenging new insights into atherogenesis. J Clin Invest. 2000;105(8):1039-41. (Pubitemid 30217686)
43. Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest. 1989;84(2):546-52. (Pubitemid 19196986)
44. Janabi M, Yamashita S, Hirano K, Matsumoto K, Sakai N, Hiraoka H, et al. Reduced adhesion of monocyte-derived macrophages from CD36-deficient patients to type I collagen. Biochem Biophys Res Commun. 2001;283(1):26-30. (Pubitemid 32912531)
45. Fraser I, Hughes D, Gordon S. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature. 1993;364(6435):343-6. (Pubitemid 23265276)
46. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6 (1):41-8. (Pubitemid 30048524)
47. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein Edeficient mice. Circulation. 1999;99(13):1726-32. (Pubitemid 29162486)
48. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386(6620):73-7. (Pubitemid 27130922)
49. Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol. 2000;20(3):715-20. (Pubitemid 30151686)
50. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized lowdensity lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334(Pt 1):9-13. (Pubitemid 28420964)
51. Chen M, Kakutani M, Naruko T, Ueda M, Narumiya S, Masaki T, et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun. 2001;282(1):153-8. (Pubitemid 32924358)
52. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999;99(24):3110-7. (Pubitemid 29289075)
53. Iwai-Kanai E, Hasegawa K, Sawamura T, Fujita M, Yanazume T, Toyokuni S, et al. Activation of lectin-like oxidized low-density lipoprotein receptor-1 induces apoptosis in cultured neonatal rat cardiac myocytes. Circulation. 2001;104(24):2948-54. (Pubitemid 33139108)
54. Mehta JL, Li DY. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun. 1998;248(3):511-4. (Pubitemid 28404451)
55. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL [LOX-1] by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20(4):1116-22. (Pubitemid 30207591)
56. Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 [LOX-1] serves as an endothelial receptor for advanced glycation end products [AGE]. FEBS Lett. 2002;511(1-3):170-4. (Pubitemid 34127844)
57. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein [LOX-1] in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999;84 (9):1043-9. (Pubitemid 29227683)
58. Murase T, Kume N, Korenaga R, Ando J, Sawamura T, Masaki T, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83(3):328-33. (Pubitemid 28371323)
59. Chen M, Nagase M, Fujita T, Narumiya S, Masaki T, Sawamura T. Diabetes enhances lectin-like oxidized LDL receptor-1 [LOX-1] expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. Biochem Biophys Res Commun. 2001;287 (4):962-8. (Pubitemid 32953570)
60. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor [LOX-1] in hypertensive rats. Biochem Biophys Res Commun. 1997;237(3):496-8. (Pubitemid 27434712)
61. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20(4):1107-15. (Pubitemid 30207590)
62. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation. 2005;112(6):812-8. (Pubitemid 41170066)
63. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kita T. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome-a pilot study. Circ J. 2010;74(7):1399-1404. Serum sLOX level is a biomarker of acute coronary syndrome. This article relates sLOX levels with prognosis after acute coronary syndromes.
64. Kamezaki F, Yamashita K, Tasaki H, Kume N, Mitsuoka H, Kita T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 correlates with oxidative stress markers in stable coronary artery disease. Int J Cardiol. 2009;134(2):285-287. This article relates serum levels of sLOX-1 with oxidative stress level in vessel wall and severity of coronary artery disease, and thus highlights the potential role of sLOX-1 as a biomarker of oxidation stress and atherosclerosis.
65. Li D, Yang B, Mehta JL. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol. 1998;275(2 Pt 2):H568-76.
66. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 2003;107(4):612-7. (Pubitemid 36176813)
67. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDLmediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101(25):2889-95. (Pubitemid 30415877)
68. Hu C, Dandapat A, Sun L, Chen J, Marwali MR, Romeo F, et al. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res. 2008;79(2):287-93. (Pubitemid 351951615)
69. Sun Y, Chen X. Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Fundam Clin Pharmacol. 2010. Ox-LDL leads to production of ROS and expression of LOX-1 on vascular smooth muscle cells via NF-κβ p65 expression and phosphorylation of JNK.
70. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100(11):1634-42. (Pubitemid 46897266)
71. Saito A, Shimizu H, Doi Y, Ishida T, Fujimura M, Inoue T, et al. Immunoliposomal drug-delivery system targeting lectin-like oxidized low-density lipoprotein receptor-1 for carotid plaque lesions in rats. J Neurosurg. 2011. The LOX-1 receptor can be potential target for prevention or cure of atherosclerosis.This article shows that liposomal drug delivery system targeting LOX-1 has decreased intimal thickness and MMP-9 in rat carotid plaque lesions.
72. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res. 2005;97(2):176-84. (Pubitemid 41033474)
73. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation. 2008;118(1):75-83.
74. Periaortic and adventitial accumulation of macrophagesin LDLr knockout mice;Modulation by LOX1 deletion.abstract#342. SSCI proceedings 2008; 2008.
75. Boger RH, Bode-Boger SM, Frolich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis. 1996;127(1):1-11. 158 (Pubitemid 26425836)
76. Curr Atheroscler Rep (2012) 14:150-159
77. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994;375(2):81-8.
78. Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med. 2011;50(7):765-776. Nitric oxide produced by eNOS dilates blood vessels and prevents atherosclerosis by maintaining endothelial function. Uncoupling of eNos generates ROS rather than NO, leading to atherosclerosis.
79. Eto H, Miyata M, Kume N, Minami M, Itabe H, Orihara K, et al. Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury. Biochem Biophys Res Commun. 2006;341(2):591-8. (Pubitemid 43152144)
80. Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21(6):955-60. (Pubitemid 34168652)
81. Yang X, Galeano NF, Szabolcs M, Sciacca RR, Cannon PJ. Oxidized low density lipoproteins alter macrophage lipid uptake, apoptosis, viability and nitric oxide synthesis. J Nutr. 1996;126(4 Suppl):1072S-5S. (Pubitemid 26105637)
82. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76(1):333-7. (Pubitemid 9110191)
83. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785-91. (Pubitemid 32880285)